Alleanza Pharmaceuticals, Inc.

Quick facts

Phase 2 pipeline

• ALZ-1101 · Neurology
  ALZ-1101 is an investigational therapeutic targeting Alzheimer's disease pathology, likely through modulation of amyloid or tau protein aggregation.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Alleanza Pharmaceuticals, Inc. portfolio CI brief
• Alleanza Pharmaceuticals, Inc. pipeline updates RSS